This study has been approved either by the Board of Records full REB or by an authorized delegated reviewer
It claimed 'GLP-1s for diabetes could be sold at a profit for just US $0.89 per month, compared to the price of $95 per month charged in Brazil, $115 per month charged in South Africa, $230 charged in Latvia and $353 charged in the US, which is a 39,562% markup over what the estimated generic price could be.' Christa Cepuch, Pharmacist Coordinator at MSF's Access Campaign, argues 'These new drugs are an absolute game changer for people living with diabetes, but are being kept out of the hands of hundreds of millions of people in low- and middle-income countries who need them' (Barber, Gotham, Bygrave
doi: 10.1038/s41430-024-01460-6 27 ChallaTDBeatonNArnoldMRudofskyGLanghansWWolfrumC
however, some patients see weight loss within a few weeks
This paper reports on kidney oxygenation, for which 80 individuals as prespecified, 20 in each group, underwent MRI
